Home Tags EpiPen

Tag: EpiPen

A new product from Novartis' Sandoz is set to launch in the first quarter of 2019 and compete directly with Mylan's EpiPen and other products.

Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky

The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.

The strange history of the EpiPen, the device developed by the military that turned into a billion-dollar business and now faces generic competition b...

Here's the story of how a common, lifesaving device became a controversial drug-pricing story, facing recalls, shortages, and now generic competition between Mylan and Teva.

Mylan stock dropped 7% after second quarter sales slumped

Mylan stock dropped over 7% after it released its second quarter earning report. The company then announced that it was to undergo a strategic review.
Mylan CEO Heather Bresch with EpiPens.

There’s a shortage of EpiPens in the US

The FDA on Wednesdsay said that there's a shortage of EpiPens in the US. Mylan, the company that distributes the emergency allergy medication, said that there are "intermittent supply constraints," but supply is available.

Mylan’s shareholders just voted against its executive pay, which included a $100 million package for its chairman

Mylan shareholders voted to re-elect the generic drugmaker's board at its annual meeting on Thursday, despite a push to to vote down most of the directors.

Advisers are telling investors to go scorched earth on the company that makes EpiPen

Shareholder advocacy groups are telling Mylan investors to show no mercy with the board at an upcoming shareholder meeting.

It sounds like the maker of EpiPen is freaking out ahead of a big shareholder meeting

Executives at Mylan, the maker of EpiPen, are richly compensated — shareholders think maybe too richly.

The chairman of the company behind the EpiPen reportedly flipped everyone off when they asked about drug pricing

Mylan's chairman reportedly did not mince words when addressing potential drug pricing criticism.

The chairman of the company behind the EpiPen made $98 million in 2016

Mylan's chairman Robert Coury made $98 million in 2016, a year in which the company faced criticism for the price of the EpiPen.

The maker of the EpiPen is being sued under a law that’s typically used to take on organized crime

The lawsuit accuses Mylan of engaging in a scheme with pharmacy benefit managers to dominate the market.